
|Videos|January 5, 2015
PFS as an Endpoint in Ovarian Cancer Clinical Trials
Author(s)Jason D. Wright, MD
Jason D. Wright, MD, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
Advertisement
Clinical Pearls
Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses progression-free survival (PFS) as an endpoint for ovarian cancer trials.
- PFS is the most commonly used endpoint for ovarian cancer clinical trials.
- PFS is relatively easily measured and can be measured in a timely fashion.
- However, PFS does not always correlate with overall survival.
Olaparib was recently approved for ovarian cancer.Read more > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































